Y-mAbs Therapeutics, Inc. (YMAB)
| Previous Close | 12.87 |
| Open | 12.96 |
| Bid | 12.01 x 200 |
| Ask | 12.11 x 100 |
| Day's Range | 11.91 - 12.96 |
| 52 Week Range | 4.60 - 20.90 |
| Volume | |
| Avg. Volume | 390,137 |
| Market Cap | 529.104M |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
Reported U.S. DANYELZA® net product revenues of $18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumesCash and cash equivalents of $75.7 million as of March 31, 2024, and cash burn of only $2.9 million for the quarter ended March 31, 2024 Management reiterates full year 2024 financial guidance and anticipated cash ru
- GlobeNewswire
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Wednesday, May 8, 2024, a
- GlobeNewswire
Y-mAbs to Present at 2024 ASCO Annual Meeting
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the acceptance of four abstracts at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 – June 4, 2024 in Chicago, IL. “This year’s ASCO p
